BROOKS — Brooks Laboratories Share Price
Last trade - 00:00- IN₹1.70bn
- IN₹1.72bn
- IN₹857.38m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.39 | ||
| Price to Tang. Book | 1.39 | ||
| Price to Free Cashflow | 29.45 | ||
| Price to Sales | 2.05 | ||
| EV to EBITDA | 29.69 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 3.31% | ||
| Return on Equity | 11.97% | ||
| Operating Margin | 5.03% | ||
Financial Summary
| Year End 31st Mar | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 911.85 | 632.05 | 794.86 | 825.57 | 857.38 | n/a | n/a | 2.11% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Brooks Laboratories Limited is an India-based pharmaceutical manufacturing company. The Company specializes in supplying pharmaceutical products to government bodies, healthcare institutions, and large organizations. It operates through two segments, which include manufacturing and trading. The manufacturing segment comprises its own manufacturing operations and loan-licensing business relating to pharmaceutical products, ingredients, and intermediaries. The trading segment comprises principal-to-principal trading activities in pharmaceutical products, ingredients, and intermediaries. Its General Products offerings include Liquid Injection (Ampoules), Liquid Injection (Vials), Dry Powder Injections (Vials), Lyophilised Injections, Eye/Ear Drops, and Nasal Drops. The Company's Critical Care Division (CCD), operates through a robust distribution network, delivering injectables to hospitals and healthcare institutions across India.
Directors
- Atul Ranchal CHM (52)
- Durga Maity CEO (49)
- Anil Pillai CFO
- Jyoti Sancheti CCO
- Rajesh Mahajan MDR (43)
- Manpreet Naroo EDR (50)
- Rajnish Bedi IND (44)
- Sonia Gupta IND
- Last Annual
- March 31st, 2026
- Last Interim
- June 30th, 2026
- Incorporated
- January 23rd, 2002
- Public Since
- September 2nd, 2011
- No. of Shareholders
- 11,028
- No. of Employees
- 347
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 29,457,248
- Address
- 201, The Sumit Business Bay,, MUMBAI, 400093
- Web
- https://www.brookslabs.net/
- Phone
- +91 1795654001
- Contact
- Prashant Rathi
- Auditors
- DMKH & CO.
Latest News for BROOKS
Upcoming Events for BROOKS
Q2 2027 Brooks Laboratories Ltd Earnings Release
Q3 2027 Brooks Laboratories Ltd Earnings Release
Similar to BROOKS
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
As of Today at 19:44 UTC, shares in Brooks Laboratories are trading at IN₹57.86. This share price information is delayed by 15 minutes.
Shares in Brooks Laboratories last closed at IN₹57.86 and the price had moved by -52.42% over the past 365 days. In terms of relative price strength the Brooks Laboratories share price has underperformed the S&P BSE 100 Index by -46.4% over the past year.
There is no consensus recommendation for this security.
Find out moreBrooks Laboratories does not currently pay a dividend.
Brooks Laboratories does not currently pay a dividend.
Brooks Laboratories does not currently pay a dividend.
To buy shares in Brooks Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹57.86, shares in Brooks Laboratories had a market capitalisation of IN₹1.70bn.
Here are the trading details for Brooks Laboratories:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: BROOKS
Based on an overall assessment of its quality, value and momentum Brooks Laboratories is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Brooks Laboratories. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -8.97%.
As of the last closing price of IN₹57.86, shares in Brooks Laboratories were trading -9.23% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Brooks Laboratories PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹57.86.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Brooks Laboratories' management team is headed by:
- Atul Ranchal - CHM
- Durga Maity - CEO
- Anil Pillai - CFO
- Jyoti Sancheti - CCO
- Rajesh Mahajan - MDR
- Manpreet Naroo - EDR
- Rajnish Bedi - IND
- Sonia Gupta - IND